{"id":82402,"date":"2026-02-06T13:45:32","date_gmt":"2026-02-06T11:45:32","guid":{"rendered":"https:\/\/synevo.md\/?post_type=product&#038;p=82402"},"modified":"2026-02-18T09:33:10","modified_gmt":"2026-02-18T07:33:10","slug":"proteina-fosfo-tau-181-screening-boala-alzheimer","status":"publish","type":"product","link":"https:\/\/old.synevo.md\/ru\/shop\/proteina-fosfo-tau-181-screening-boala-alzheimer\/","title":{"rendered":"Proteina fosfo-Tau 181 (screening boala Alzheimer)"},"content":{"rendered":"<h3 data-asw-org-font-size=\"18\"><strong>Informa\u021bii generale: Proteina fosfo-Tau 181 (screening boala Alzheimer)<\/strong><\/h3>\n<p data-asw-org-font-size=\"16\"><a href=\"https:\/\/www.synevo.ro\/informatii-medicale\/boala-alzheimer-cauza-dementei\/\" data-asw-org-font-size=\"16\" rel=\"nofollow noopener\" target=\"_blank\">Boala Alzheimer<\/a> (AD) reprezint\u0103 una dintre cele mai importante provoc\u0103ri medicale ale secolului XXI, cu un impact major asupra s\u0103n\u0103t\u0103\u021bii publice \u0219i a sistemelor de \u00eengrijire medical\u0103 la nivel global. Diagnosticul precoce al acestei afec\u021biuni r\u0103m\u00e2ne o problem\u0103 semnificativ\u0103, deoarece simptomele clinice devin evidente abia \u00eentr-un stadiu avansat al neurodegener\u0103rii. \u00cen prezent, p\u00e2n\u0103 la 75% dintre pacien\u021bii care prezint\u0103 simptome sugestive pentru boala Alzheimer nu primesc un diagnostic corect \u0219i \u00een timp util, iar intervalul mediu dintre debutul simptomelor \u0219i stabilirea diagnosticului este de aproximativ trei ani. \u00cen acest context, identificarea unor biomarkeri fiabili, accesibili \u0219i minim invazivi este o prioritate strategic\u0103 pentru medicina modern\u0103.<\/p>\n<p data-asw-org-font-size=\"16\">Unul dintre ace\u0219ti biomarkeri este proteina fosfo-Tau 181 (pTau181) determinat\u0103 din plasm\u0103, o component\u0103 esen\u021bial\u0103 \u00een lan\u021bul patogenetic al bolii Alzheimer \u0219i un instrument diagnostic cu poten\u021bial major \u00een practica clinic\u0103 curent\u0103.<\/p>\n<p data-asw-org-font-size=\"16\">Proteina Tau este o protein\u0103 asociat\u0103 microtubulilor, exprimat\u0103 \u00een special \u00een neuronii sistemului nervos central. \u00cen condi\u021bii fiziologice, Tau stabilizeaz\u0103 microtubulii \u0219i contribuie la transportul axonal eficient. \u00cen boala Alzheimer, proteina Tau sufer\u0103 modific\u0103ri post-transla\u021bionale, \u00een special hiperfosforilare, ceea ce determin\u0103 pierderea afinit\u0103\u021bii pentru microtubuli, destabilizarea acestora \u0219i agregarea proteinei sub form\u0103 de filamente helicoidale pereche. Aceste agregate formeaz\u0103 \u201c\u00eencurc\u0103turi\u201d (ghemuri) neurofibrilare (neurofibrillary tangles) \u2014 una dintre cele dou\u0103 leziuni histopatologice majore ale AD, al\u0103turi de pl\u0103cile amiloide extracelulare.<\/p>\n<p data-asw-org-font-size=\"16\">Fosforilarea proteinei Tau poate avea loc \u00een mai multe situsuri. Dintre acestea, reziduul de treonin\u0103 181 este deosebit de important, deoarece fosforilarea \u00een acest punct (pTau181) este puternic corelat\u0103 cu prezen\u021ba \u0219i extinderea patologiei neurofibrilare. Cre\u0219terea concentra\u021biei pTau181 reflect\u0103 acumularea anormal\u0103 de Tau \u00een creier \u0219i este considerat\u0103 un marker specific pentru boala Alzheimer, cu sensibilitate \u0219i specificitate ridicate \u00een discriminarea fa\u021b\u0103 de alte cauze de demen\u021b\u0103.<\/p>\n<p data-asw-org-font-size=\"16\">Determinarea pTau181 plasmatic se bazeaz\u0103 pe tehnologii imunologice ultrasensibile, cum ar fi ECLIA (electrochemiluminiscen\u021b\u0103). Testul Elecsys pTau181 Plasma, prima metod\u0103 IVDR certificat\u0103 \u00een Uniunea European\u0103 pentru determinarea pTau181 \u00een plasm\u0103 ca test de diagnostic in vitro.<\/p>\n<p data-asw-org-font-size=\"16\">Printr-un singur prag de referin\u021b\u0103 (\u201ecut-off\u201d), testul permite excluderea bolii Alzheimer asociate cu patologie amiloid\u0103, cu o valoare predictiv\u0103 negativ\u0103 ridicat\u0103.<\/p>\n<p data-asw-org-font-size=\"16\">Valorile crescute ale pTau181 plasmatic sunt corelate cu prezen\u021ba patologiei amiloidice \u0219i tau la nivel cerebral, confirmat\u0103 prin PET sau analiza LCR. Numeroase studii au demonstrat o corela\u021bie direct\u0103 \u00eentre concentra\u021bia plasmatic\u0103 de pTau181 \u0219i stadiul bolii, de la stadiile prodromale p\u00e2n\u0103 la demen\u021ba Alzheimer manifest\u0103.<\/p>\n<p data-asw-org-font-size=\"16\">Utilizarea acestui biomarker \u00een practica clinic\u0103 aduce mai multe beneficii:<\/p>\n<ul>\n<li data-asw-org-font-size=\"16\">Screening ini\u021bial al pacien\u021bilor cu tulbur\u0103ri cognitive, \u00eenainte de trimiterea c\u0103tre investiga\u021bii costisitoare sau invazive;<\/li>\n<li data-asw-org-font-size=\"16\">Trierea pacien\u021bilor care ar beneficia de investiga\u021bii suplimentare (PET, LCR);<\/li>\n<li data-asw-org-font-size=\"16\">Reducerea num\u0103rului de investiga\u021bii inutile la pacien\u021bii cu test negativ<\/li>\n<\/ul>\n<p data-asw-org-font-size=\"16\">Un rezultat negativ la pTau181 plasmatic are o valoare predictiv\u0103 negativ\u0103 foarte mare, ceea ce \u00eenseamn\u0103 c\u0103 probabilitatea de a avea patologie amiloidic\u0103 este foarte sc\u0103zut\u0103, iar pacientul poate fi direc\u021bionat c\u0103tre alte investiga\u021bii sau monitorizat \u00een timp. Un rezultat pozitiv nu confirm\u0103 boala Alzheimer \u00een mod absolut, dar indic\u0103 necesitatea unor investiga\u021bii suplimentare.<\/p>\n<p data-asw-org-font-size=\"16\">Un avantaj suplimentar al pTau181 este specificitatea crescut\u0103 pentru boala Alzheimer, \u00een compara\u021bie cu alte forme de demen\u021b\u0103, cum ar fi demen\u021ba frontotemporal\u0103 (FTD), demen\u021ba vascular\u0103 sau boala Parkinson cu demen\u021b\u0103. Studiile arat\u0103 c\u0103 pTau181 are o capacitate superioar\u0103 de a distinge AD de FTD, cu o acurate\u021be diagnostic\u0103 comparabil\u0103 cu cea a LCR.<\/p>\n<p data-asw-org-font-size=\"16\">Aceast\u0103 specificitate are implica\u021bii majore \u00een alegerea tratamentului, \u00eentruc\u00e2t terapiile anti-amiloidice aflate \u00een dezvoltare (de ex. anticorpi monoclonali) sunt utile exclusiv la pacien\u021bii cu AD confirmat.<\/p>\n<p data-asw-org-font-size=\"16\">pTau181 este primul marker plasmatic pentru boala Alzheimer aprobat \u00een Europa, dar face parte dintr-o genera\u021bie emergent\u0103 de biomarkeri ce includ \u0219i pTau217, pTau231, A\u03b242\/40 \u0219i GFAP (glial fibrillary acidic protein). Combina\u021bia acestora \u00eentr-un panel multimarker va permite diagnosticul etiologic precis \u00eenc\u0103 din stadiile presimptomatice ale bolii.<\/p>\n<p data-asw-org-font-size=\"16\">De asemenea, utilizarea biomarkerilor plasmatici va facilita screeningul popula\u021bional, selectarea pacien\u021bilor pentru terapii \u021bintite \u0219i monitorizarea eficacit\u0103\u021bii tratamentului \u00een timp real.<\/p>\n<p data-asw-org-font-size=\"16\">Determinarea pTau181 plasmatic reprezint\u0103 un progres major \u00een diagnosticul bolii Alzheimer, oferind un test accesibil, minim invaziv \u0219i cu acurate\u021be comparabil\u0103 cu metodele de referin\u021b\u0103. Acest biomarker permite identificarea precoce a pacien\u021bilor cu probabilitate crescut\u0103 de patologie amiloidic\u0103, reduc\u00e2nd nevoia de investiga\u021bii invazive \u0219i facilit\u00e2nd accesul la tratament \u0219i \u00eengrijire personalizat\u0103.<\/p>\n<p data-asw-org-font-size=\"16\">\u00centr-un context \u00een care num\u0103rul pacien\u021bilor cu tulbur\u0103ri cognitive este \u00een cre\u0219tere, iar terapiile specifice devin disponibile, integrarea pTau181 \u00een practica clinic\u0103 de rutin\u0103 va reprezenta un pas strategic c\u0103tre medicina personalizat\u0103 \u00een neurologie.<\/p>\n<p data-asw-org-font-size=\"16\"><strong>Termenul de eliberare a rezultatelor este de 11 zile lucr\u0103toare.<\/strong><\/p>\n<h3 data-asw-org-font-size=\"18\"><strong>Preg\u0103tirea pacientului:\u00a0<\/strong><\/h3>\n<p data-asw-org-font-size=\"16\">Nu este necesar\u0103 o preg\u0103tire special\u0103; se recomand\u0103 recoltarea a jeun sau la minimum dou\u0103 ore dup\u0103 mas\u0103.<\/p>\n<p data-asw-org-font-size=\"16\"><strong>Specimen recoltat:<\/strong> S\u00e2nge venos<\/p>\n<p data-asw-org-font-size=\"16\"><strong>Recipient de recoltare<\/strong>: Vacutainer EDTA cu gel (tub cu capac sidefiu)<\/p>\n<p data-asw-org-font-size=\"16\"><strong>Prelucrare necesar\u0103 dup\u0103 recoltare:<\/strong> Separarea plasmei prin centrifugare<\/p>\n<p data-asw-org-font-size=\"16\"><strong>Stabilitatea probei: <\/strong>Plasma este stabil\u0103 7 zile la 2\u20138\u00b0C sau 3 luni la \u221220\u00b0C<\/p>\n<p data-asw-org-font-size=\"16\"><strong>Cauze de respingere a probei: <\/strong>Proba intens hemolizat\u0103, lipemic\u0103 sau depozitat\u0103 \u00een condi\u021bii necorespunz\u0103toare<\/p>\n<p data-asw-org-font-size=\"16\"><strong>Metod\u0103:<\/strong> ECLIA (Electrochemiluminiscen\u021b\u0103)<\/p>\n<h3 data-asw-org-font-size=\"18\"><strong>Interval de referin\u021b\u0103:\u00a0<\/strong><\/h3>\n<p data-asw-org-font-size=\"16\">0,3\u20131,9 pg\/mL.<\/p>","protected":false},"excerpt":{"rendered":"<p>Informa\u021bii generale: Proteina fosfo-Tau 181 (screening boala Alzheimer) Boala Alzheimer (AD) reprezint\u0103 una dintre cele mai importante provoc\u0103ri medicale ale secolului XXI, cu un impact major asupra s\u0103n\u0103t\u0103\u021bii publice \u0219i a sistemelor de \u00eengrijire medical\u0103 la nivel global. Diagnosticul precoce al acestei afec\u021biuni r\u0103m\u00e2ne o problem\u0103 semnificativ\u0103, deoarece simptomele clinice devin evidente abia \u00eentr-un stadiu &hellip; <a href=\"https:\/\/old.synevo.md\/ru\/shop\/proteina-fosfo-tau-181-screening-boala-alzheimer\/\">Continued<\/a><\/p>","protected":false},"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[953],"product_tag":[],"class_list":{"0":"post-82402","1":"product","2":"type-product","3":"status-publish","5":"product_cat-teste-de-biochimie","7":"first","8":"instock","9":"shipping-taxable","10":"purchasable","11":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product\/82402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/comments?post=82402"}],"wp:attachment":[{"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/media?parent=82402"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product_brand?post=82402"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product_cat?post=82402"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/old.synevo.md\/ru\/wp-json\/wp\/v2\/product_tag?post=82402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}